Global Patchwork Of Bribery Laws Complicates GSK Defense

Law360, New York (August 6, 2013, 8:45 PM EDT) -- The involvement of U.S., U.K. and Chinese regulators in the GlaxoSmithKline PLC bribery investigation may create headaches for the pharmaceutical giant as it fights claims under three separate legal regimes, underscoring the challenge of mounting a global anti-corruption defense, attorneys say.

The British firm said July 22 that some of its senior executives in China may have bribed physicians and hospitals to boost drug sales. Chinese state media later reported that officials there had detained at least 18 GSK employees in connection with the scandal. Regulators...
To view the full article, register now.